The combination of favezelimab (anti-Lag3) and pembrolizumab (anti-PD-1) is in PhIII studies for colorectal cancer and non-Hodgkin’s lymphoma; the combination of fianlimab (anti-Lag3) and cemiplimab (anti-PD-1) is in PhIII studies for non-small cell lung cancer and melanoma. This evidence concerns the gene LAG3 and non-Hodgkin lymphoma.